Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aztreonam inhalation - Gilead Sciences

Drug Profile

Aztreonam inhalation - Gilead Sciences

Alternative Names: AI - Gilead; AZLI; Aztreonam lysine; Cayston; Corus 1020; GS-9268

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Class Antibacterials; Monobactams; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis-associated respiratory tract infections
  • Discontinued Bronchiectasis; Burkholderia infections

Most Recent Events

  • 16 Jun 2020 Gilead Sciences suspends a phase II trial in Bronchiectasis prior to enrolment in Scotland (NCT03696290) (EudraCT2018-001590-24)
  • 29 Jan 2020 Aztreonam inhalation is still in phase III trials for Cystic fibrosis-associated respiratory tract infections (In adolescents, In children, In infants) in USA and Spain (NCT03219164)
  • 18 Jan 2020 Phase-III clinical trials in Cystic fibrosis-associated respiratory tract infections (In adolescents, In children, In infants) in Greece, United Kingdom, Netherlands, Italy, Israel, Germany, France, Denmark, Belgium, Austria (Inhalation) before January 2020 (NCT03219164)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top